Nasopharyngeal carcinoma (NPC) is a squamous cell carcinoma that is especially prevalent in southern China. Despite improvements in the locoregional control rate due to the development of more precise imaging and radiotherapy (RT) and eradication of potential metastasis by chemotherapy, the survival of patients with advanced NPC remains unsatisfactory. Therefore, it is necessary to identify novel prognostic factors to recognise patients at high risk. As we know, Epstein--Barr virus (EBV) ([@bib6]), southern Chinese tradition of consuming salted fish ([@bib31]; [@bib4]) and cigarette smoking ([@bib29]) all play important roles in the aetiology. There is also substantial evidence for a hereditable component in developing NPC based on segregation studies, linkage analysis and candidate gene/genome-wide association studies ([@bib10]; [@bib13]; [@bib2]). Importantly, family history of NPC has consistently been associated with an increased risk of developing the disease ([@bib15]; [@bib11]; [@bib14]; [@bib30]). A large case--control study ([@bib26]) even provided clear evidence that the risk of NPC was associated with a first-degree family history of cancers, including NPC and cancers of the head and neck, lung and breast. So it arouses a question -- whether family history of NPC is associated with survival among patients with established NPC. Recently, the associations between family history and cancer survival have been studied in other cancers. Colon cancer ([@bib3]; [@bib32]) and gastric cancer ([@bib12]) patients with a first-degree family history showed a significant reduction in recurrence and death. Breast cancer patients with family history of breast cancer had a better prognosis as well ([@bib23]). However, the association of family history and NPC survival has not been explored up to now. Therefore, we performed this study to evaluate the effect of a first-degree family history of NPC on the clinicopathologic characteristics and survival of patients with NPC.

Materials and methods
=====================

Patient characteristics
-----------------------

The study was reviewed and approved by the Human Ethics Approval Committee at Sun Yat-sen University Cancer Center. Between January 2005 and May 2007, 2103 NPC patients who were hospitalised at the Sun Yat-sen University Cancer Center were potentially eligible for inclusion in this retrospective study. A total of 1773 patients were eventually included who (1) were newly diagnosed, biopsy-proven, non-metastatic NPC patients without previous anticancer treatment, (2) were at the age of 20 or \>20 years and born in southern China, (3) had a complete pretreatment evaluation including patient history, physical examination, haematology and biochemistry profiles, magnetic resonance imaging (MRI) of the nasopharynx and neck, chest radiography, abdominal sonography and a whole-body bone scan using single-photon emission computed tomography and (4) had a complete interview about family history, education and lifestyle behaviour.

Medical records were reviewed to extract data on basic characteristics including age, gender, education degree, cigarette smoking status at diagnosis (never/current/former smoker), alcohol drinking status at diagnosis (never/current/former drinker), pretreatment titre of serum immunoglobulin A against EBV viral capsid antigen (VCA-IgA), pathology ([@bib27]) and family history. Current smokers/drinkers were defined as patients who smoked/drank at diagnosis or had stopped for \<1 year. Former smokers/drinkers were patients who had stopped smoking or drinking for at least 1 year before treatment. All patients were restaged according to the seventh edition of the UICC/AJCC staging system ([@bib8], [@bib9]).

Treatment
---------

All patients were treated by definitive RT. Details of the radiation techniques have been described previously ([@bib22]; [@bib5]). In addition, institutional guidelines recommended no chemotherapy for patients in stages I and II and induction, concurrent and adjuvant chemotherapy or combination treatment for those in stages III and IV. Induction or adjuvant chemotherapy consisted of cisplatin with 5-fluorouracil, cisplatin with taxoids or triplet of cisplatin and 5-fluorouracil plus taxoids every 3 weeks for two to three cycles. Concurrent chemotherapy consisted of cisplatin given on weeks 1, 4 and 7 of RT or cisplatin given weekly.

Family history assessment
-------------------------

Family history of cancer was ascertained by interviewing patients themselves and/or their family members at the time of case diagnosis. A positive family history was classified according to first degree, second degree or third degree. If the subjects had family history in several degrees of relatives, they were regarded as having a family history of closer degree in blood. We recorded the number of first-degree family members with NPC.

Follow-up
---------

Patients were followed up every 3 months during the first 2 years and every 6 months thereafter until death. The assessments were performed by history and physical examination and nasopharyngoscopy at each follow-up visit. Local relapses were confirmed by biopsy, MRI scan or both. Regional relapses were diagnosed by clinical examination of the neck and, in doubtful cases, by fine-needle aspiration or an MRI scan of the neck. Distant metastases were diagnosed by clinical symptoms, physical examinations and imaging methods including chest radiography, bone scan, MRI and abdominal sonography. Patients with relapse, distant metastasis or in persistent disease were delivered with salvage treatment including reirradiation, chemotherapy and surgery. The follow-up duration was calculated from the first day of therapy to either the day of death or the day of the last examination.

Study end points
----------------

Our primary end point was overall survival (OS), defined as the time from treatment to death resulting from any cause. Secondary end points were locoregional relapse-free survival (LRFS) and distant metastasis-free survival (DMFS), defined as the time from treatment to the first locoregional relapse and distant metastasis, respectively.

Statistical methods
-------------------

All end points were examined using Kaplan--Meier methods and the log-rank test ([@bib16]). Univariate stratified survival analyses were performed with hazard ratios (HRs) and 95% confidence intervals (CIs). Multivariate analyses were performed using the Cox proportional hazards model ([@bib7]), adjusting for important prognostic factors. Comparisons of demographic, clinical and pathologic variables were performed using *χ*^2^ statistic or Fisher\'s exact test for nominal variables as appropriate. Two-sided *P*-values \<0·05 were considered to be significant. All tests were conducted using SPSS 16.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Demographic and clinicopathologic characteristics
-------------------------------------------------

A total of 1773 NPC patients were entered into this study (inclusion flow chart was presented in [Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). Within a median follow-up duration of 71 months (range: 1--94 months) for the entire population and 74 months (range: 7--94 months) and 70 months (range: 1--94 months) for patients with and without a first-degree family history of NPC, 184/1773 (10.4%), 20/207 (9.7%) and 164/1566 (10.5%) patients were lost to follow up, respectively. Of these, 207/1773 (11.7%) patients had a family history of NPC in first-degree relatives and 52/1773 (2.9%) in second- and third-degree relatives. Fifteen of the 207 patients had both first- and second-/third-degree family history of NPC. Furthermore, 173/1773 (9.8%) patients had only one first-degree relative affected by NPC and 34/1773 (1.9%) had at least two affected first-degree family members.

The demographic and clinicopathologic characteristics of patients were compared according to with or without a first-degree family history of NPC ([Table 1](#tbl1){ref-type="table"}). There were no differences in the distributions of age group, gender, education degree, cigarette smoking status (never/current/former smoker), alcohol drinking status (never/current/former drinker), pretreatment titre of VCA-IgA (⩽1 : 160 *vs* \>1 : 160), pathology (I/II/III) and radiation technique (all *P*-values ⩾0.171).

Significant differences were observed in T stage, N stage, clinical stage and chemotherapy regimens. For patients with a first-degree family history of NPC, the proportion of advanced T stage, N stage and clinical stage was lower, and accordingly, the proportion of adding chemotherapy to RT was also lower that than for those without a family history of NPC.

Effect of family history on survival
------------------------------------

A first-degree family history of NPC was associated with a significant reduction in the risk of death ([Figure 1](#fig1){ref-type="fig"}). The 5-year OS rate was 92.6% for patients with a first-degree family history compared with 80.7% for those without such a profile (HR=0.41, 95% CI, 0.26--0.65; *P*\<0.001). This remained unchanged after accounting for other important prognostic factors, including age group (categorical), gender, education degree (categorical), smoking status (never/current/former smoker), drinking status (never/current/former drinker), titre of VCA-IgA (⩽1 : 160 *vs* \>1 : 160), pathology (I/II/III), T stage (T1/T2/T3/T4), N stage (N0/N1/N2/N3), chemotherapy regimens and radiation technique. Compared with patients without a first-degree family history, those with a family history of NPC had a multivariate HR of 0.60 (95% CI, 0.37--0.98; *P*=0.040) for death ([Table 2](#tbl2){ref-type="table"}). Furthermore, the results for the risk of locoregional relapse and distant metastasis were quite similar to those for death. In univariate analysis, a first-degree family history of NPC was associated with improved LRFS (unadjusted HR=0.51, 95% CI, 0.28--0.95; *P*=0.033) and DMFS (unadjusted HR=0.43, 95% CI, 0.25--0.75; *P*=0.003) ([Figure 1](#fig1){ref-type="fig"}). In multivariate analyses, adjusted HRs for LRFS and DMFS were 0.52 (95% CI, 0.24--1.12; *P*=0.096) and 0.51 (95% CI, 0.27--0.97; *P*=0.040) ([Table 2](#tbl2){ref-type="table"}).

To specify the influence of family history on survival, we conducted second analyses ([Table 2](#tbl2){ref-type="table"}). First, compared with patients without a first-degree family history of NPC, those with one affected relative had a multivariate HR of 0.61 (95% CI, 0.36--1.02; *P*=0.059) for OS, 0.52 (95% CI, 0.23--1.18; *P*=0.118) for LRFS and 0.53 (95% CI, 0.27--1.03; *P*=0.062) for DMFS. For participants with two or more affected first-degree relatives, we observed a multivariate HR of 0.57 (95% CI, 0.14--2.28; *P*=0.423) for OS, 0.54 (95% CI, 0.07--3.88; *P*=0.538) for LRFS and 0.41 (95% CI, 0.06--2.91; *P*=0.369) for DMFS. So there was a trend for reduction of overall mortality, locoregional relapse and distant metastasis with an increasing number of affected family members (*P*-values for trend were 0.050, 0.114 and 0.044, respectively). Second, compared with patients without a second- or third-degree family history of NPC, those with such a profile had a multivariate HR of 0.92 (95% CI, 0.41--2.08; *P*=0.841) for OS, 0.61 (95% CI, 0.15--2.47; *P*=0.486) for LRFS and 0.39 (95% CI, 0.10--1.58; *P*=0.186) for DMFS. Hence, second- and third-degree family history of NPC was not significantly associated with survival. Finally, we further addressed the concern that patients with a family history of NPC might have a different prognosis related to earlier detection of their cancers. Among stage III and IV patients, we observed a multivariate HR of 0.57 (95% CI, 0.34--0.95; *P*=0.033) for OS, 0.54 (95% CI, 0.24--1.23; *P*=0.143) for LRFS and 0.49 (95% CI, 0.25--0.96; *P*=0.036) for DMFS when comparing patients with or without a first-degree family history of NPC. These results were quite similar to those for the entire population. Among stage I and II patients, the adjusted HRs for OS, LRFS and DMFS were 0.31 (95% CI, 0.07--1.34; *P*=0.117), 0.39 (95% CI, 0.05--2.99; *P*=0.364) and 0.31 (95% CI, 0.04--2.35; *P*=0.257), respectively. The OS curves of patients in stages I plus II, III and IV with or without a first-degree family history of NPC were presented in [Supplementary Figure 2](#sup1){ref-type="supplementary-material"}.

In addition, we also assessed the association between a first-degree family history of NPC and OS across strata of other potential predictors of patient outcome ([Table 3](#tbl3){ref-type="table"}). The effect of family history on the risk of death was not significantly modified by age, education degree, smoking and drinking status or titre of VCA-IgA. However, the benefit of family history in decreasing risk of death was restricted to male patients (adjusted HR=0.55, 95% CI, 0.30--0.98; *P*=0.043). Moreover, a family history of NPC had significant association with OS among patients treated with addition of chemotherapy to RT and with conventional radiation technique (adjusted HR=0.57, 95% CI, 0.34--0.95, *P*=0.033 and adjusted HR=0.55, 95% CI, 0.31--0.96, *P*=0.037, respectively).

Discussion
==========

Several studies have demonstrated that family history of NPC increased the risk of developing NPC ([@bib15]; [@bib11]; [@bib14]; [@bib30]). However, to date, no studies have examined the influence of family history of NPC on subsequent outcomes in patients with established cancer. This study included 1773 NPC patients, among which 207 (11.7%) had a family history of NPC in first-degree relatives. We demonstrated that a first-degree family history of NPC was associated with a significant reduction in risk of death, locoregional relapse and distant metastasis, and it remained unchanged after adjusting for known prognostic factors. Our findings were quite similar to previous studies in colorectal cancer ([@bib32]; [@bib25]), colon cancer ([@bib3]), gastric cancer ([@bib12]) and breast cancer ([@bib23]).

We then examined the effects according to the number of affected first-degree family members; resultantly, a significant trend for improvement in DMFS and OS with an increasing number of first-degree family members was observed. Whereas in second- or third-degree relatives, the effects of family history were not observed, which were consistent with reports in gastric cancer ([@bib12]) and breast cancer ([@bib24], [@bib23]). Further investigations are required because this nonsignificant differential survival seemed to be driven by the small sample size of cases with a second- or third-degree family history of NPC. Additionally, we performed stratified analysis according to clinical stage and found significant effects of family history only in locoregionally advanced stage patients. This may mainly result from a large number of patients and high event rates in the advanced clinical stage stratum; the interactions between clinical stage and a first-degree family history of NPC (*P*\<0.001) may also contribute to it. Individuals with a family history of the disease in first-degree relatives might be more likely to undergo regular NPC surveillance, such as Epstein--Barr virus antibodies and DNA copies, and had relatively early clinical stage as shown in [Table 1](#tbl1){ref-type="table"}. Despite of adjusting for smoking status and other prognostic factors, we found that the effects of family history were restricted to male patients. A recent study ([@bib21]) revealed that the female sex was positively associated with an early T stage, N stage and clinical stage; reduced disease progression and cancer-related deaths and was a favourable independent prognostic factor. This suggested that some intrinsic features of the female sex should interact and confound the effects of family history. But we detected no interactions between gender and a first-degree family history of NPC (*P*=0.366). Therefore, the significant differences of the effects of a first-degree family history in male and female patients seem to be true if the influence of small sample size in male stratum is excluded. Moreover, we found that the effect of family history was restricted in patients treated with addition of chemotherapy to RT. Unfortunately, there were significant interactions between chemotherapy (yes/no) and a first-degree family history of NPC (*P*=0.046). As shown in [Table 1](#tbl1){ref-type="table"}, patients with a family history of NPC had an obvious higher proportion of RT alone treatment than patients without a family history of NPC. So it remains uncertain whether the favourable prognostic value of family history is applicable to patients with RT alone. Finally, the effect of family history was observed only in patients treated with conventional radiation technique, and no interaction between radiation technique and a first-degree family history of NPC was showed (*P*=0.553) when we include an interaction term in the model. This differentiation was mainly due to a higher proportion of advanced stage patients among this group than those treated with intensity-modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT). Meanwhile, there were low proportion of patients treated with IMRT/3DCRT and a few events in the group of positive family history. This may partially explain no effects of family history in patients treated with IMRT/3DCRT.

A major limitation of our study is that we relied on self-reported family history and might possibly misclassify family history status, especially under-reporting the second-degree family history. But prior studies have demonstrated such data to be reliable ([@bib1]; [@bib17]). Another limitation is that we could not collect information on the age at which the first-degree relative was diagnosed with NPC, as the effect of family history might be different according to it. The third concern was that we failed to include data regarding pretreatment plasma EBV DNA concentrations, which had been demonstrated to strongly predict survival of NPC ([@bib20]; [@bib18]). However, we performed stratified analysis according to pretreatment serum EBV VCA-IgA antibody, another significant prognostic factor for survival ([@bib19]), albeit DNA concentrations seemed to be superior to it in prognostic predictions for NPC ([@bib28]). Studies based on EBV DNA concentrations are being planned. Moreover, the chemotherapy regimens were not totally identified with the latest NCCN guideline for different criteria of staging systems and development of treatment regimen. During the period when patients were treated, many patients were encouraged to participate in randomised trials, which also resulted in heterogeneous treatment strategies. But we conducted multivariate analyses accounting for RT technique and chemotherapy regimens. Additionally, the smoking and drinking status questionnaire was not administered during follow-up; we were unable to fully adjust for the confounding effects by smoking and drinking status at diagnosis alone. But to date, no studies have demonstrated the role of cigarette smoking or alcohol intake during or after treatment in affecting survival of NPC. In this study, we accounted for socioeconomic status by education degree alone; this limitation cannot be neglected as well. We are planning to detect the prognostic value of pretreatment body mass index -- another factor partially representing socioeconomic status.

More importantly, it is not clear why a first-degree family history of NPC affects survival of patients. Our study showed more early-stage patients among those with a family history of NPC, which strongly supports an assumption of surveillance monitoring for individuals with a family history of NPC. Health-related behaviour may also explain our observations, as found in gastric cancer ([@bib12]). Yet we here did not observe significant differences in the proportion of smokers or drinkers in patients with or without a family history of NPC. Underlying molecular and pathogenic differences might play an intrinsic role in the effect of family history, although we observed no significantly different distribution of VCA-IgA and pathology in patients with and without a family history of NPC. Further basic researches into genetic differences were needed to fully elucidate the potential mechanisms.

To summarise, this study, as the first one, showed better survival for patients who had a first-degree family history of NPC than for patients without this profile. Further studies are needed to explore the biological, genetic or behavioural differences in NPC according to the presence of family history.
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![**(**A**) OS, (**B**) LRFS and (**C**) DMFS curves of patients with and without a first-degree family history of NPC.**      .](bjc2013343f1){#fig1}

###### Demographic and clinicopathologic characteristics by with or without an FD-FH-NPC

                                                   **With FD-FH-NPC (*****n*****=207)**   **Without FD-FH-NPC (*****n*****=1566)**                 
  ------------------------------------------------ -------------------------------------- ------------------------------------------ ------ ------ ------------------------------------
  **Age group (years)**                                                                                                                            0.723
  20--30                                           8                                      3.9                                        94     6.0     
  31--40                                           62                                     30.0                                       424    27.1    
  41--50                                           67                                     32.4                                       503    32.1    
  51--60                                           47                                     22.7                                       363    23.2    
  ⩾61                                              23                                     11.1                                       182    11.6    
  **Gender**                                                                                                                                       0.171
  Male                                             148                                    71.5                                       1188   75.9    
  Female                                           59                                     28.5                                       378    24.1    
  **Education degree**                                                                                                                             0.237
  Illiterate                                       11                                     5.3                                        84     5.4     
  Primary                                          56                                     27.1                                       516    33.0    
  Secondary                                        105                                    50.7                                       763    48.7    
  Higher                                           35                                     16.9                                       203    13.0    
  **Smoking status**[a](#t1-fn2){ref-type="fn"}                                                                                                    0.806
  Current smoker                                   77                                     37.2                                       619    39.5    
  Former smoker                                    21                                     10.1                                       149    9.5     
  Never smoker                                     109                                    52.7                                       798    51.0    
  **Drinking status**[a](#t1-fn2){ref-type="fn"}                                                                                                   0.766
  Current drinker                                  24                                     11.6                                       207    13.2    
  Former drinker                                   4                                      1.9                                        25     1.6     
  Never drinker                                    179                                    86.5                                       1334   85.2    
  **VCA-IgA**                                                                                                                                      0.495
  ⩽1 : 160                                         107                                    51.7                                       770    49.2    
  \>1 : 160                                        100                                    48.3                                       796    50.8    
  **Pathology**[b](#t1-fn3){ref-type="fn"}                                                                                                         0.315[c](#t1-fn4){ref-type="fn"}
  I                                                0                                      0                                          6      0.4     
  II                                               7                                      3.4                                        86     5.5     
  III                                              200                                    96.6                                       1474   94.1    
  **T stage**                                                                                                                                      0.001
  T1                                               36                                     17.4                                       205    13.1    
  T2                                               72                                     34.8                                       398    25.4    
  T3                                               70                                     33.8                                       589    37.6    
  T4                                               29                                     14.0                                       374    23.9    
  **N stage**                                                                                                                                      0.002
  N0                                               50                                     24.2                                       263    16.8    
  N1                                               124                                    59.9                                       883    56.4    
  N2                                               29                                     14.0                                       377    24.1    
  N3                                               4                                      1.9                                        43     2.7     
  **Clinical stage**                                                                                                                               \<0.001
  I                                                16                                     7.7                                        71     4.5     
  II                                               76                                     36.7                                       396    25.3    
  III                                              82                                     39.6                                       690    44.1    
  IVa                                              29                                     14.0                                       366    23.4    
  IVb                                              4                                      1.9                                        43     2.7     
  **Chemotherapy regimens**                                                                                                                        \<0.001[c](#t1-fn4){ref-type="fn"}
  None                                             70                                     33.8                                       357    22.8    
  IC                                               27                                     13.0                                       412    26.3    
  CCRT                                             69                                     33.3                                       429    27.4    
  IC+CCRT                                          33                                     15.9                                       292    18.6    
  CCRT+AC                                          5                                      2.4                                        58     3.7     
  IC+CCRT+AC                                       3                                      1.4                                        18     1.1     
  **Radiation technique**                                                                                                                          0.943[c](#t1-fn4){ref-type="fn"}
  IMRT                                             49                                     23.7                                       375    23.9    
  3DCRT                                            5                                      2.4                                        31     2.0     
  Conventional                                     153                                    73.9                                       1160   74.1    

Abbreviations: AC=adjuvant chemotherapy; CCRT=concurrent chemoradiotherapy; FD-FH-NPC=first-degree family history of nasopharyngeal carcinoma; IC=induction chemotherapy; IMRT=intensity-modulated radiotherapy; VCA-IgA=immunoglobulin A against Epstein--Barr virus viral capsid antigen; WHO=World Health Organization; 3DCRT=three-dimensional conformal radiotherapy.

Current smokers/drinkers are defined as patients who smoke/drink at diagnosis or have stopped for \<1 year. Former smokers/drinkers are patients who have stopped smoking or drinking for at least 1 year before treatment.

Based on the criteria of WHO histological type (1991): I=squamous cell carcinomas; II=differentiated non-keratinising carcinoma; III=undifferentiated non-keratinising carcinoma.

*P*-values by Fisher\'s exact probability test and all others by Pearson\'s *χ*^2^ test.

###### Multivariate analysis for OS, LRFS and DMFS[a](#t2-fn2){ref-type="fn"}

                                                                **OS**  **LRFS**            **DMFS**                                                               
  ----------------------------------------------------- ------ -------- ------------------- ---------- ----- ------------------- ------- ----- ------------------- -------
  **FD-FH-NPC**                                                                                                                                                    
  Without                                                1566    338    1.00                            148  1.00                         213  1.00                 
  With                                                   207      20    0.60 (0.37--0.98)   0.040       11   0.52 (0.24--1.12)   0.096    13   0.51 (0.27--0.97)   0.040
  **A second- or third-degree family history of NPC**                                                                                                              
  No                                                     1721    352    1.00                            157  1.00                         224  1.00                 
  Yes                                                     52      6     0.92 (0.41--2.08)   0.841        2   0.61 (0.15--2.47)   0.486     2   0.39 (0.10--1.58)   0.186
  **Number of first-degree relatives with NPC**                                                                                                                    
  0                                                      1566    338    1.00                            148  1.00                         213  1.00                 
  1                                                      173      17    0.61 (0.36--1.02)   0.059        9   0.52 (0.23--1.18)   0.118    11   0.53 (0.27--1.03)   0.062
  ⩾2                                                      34      3     0.57 (0.14--2.28)   0.423        2   0.54 (0.07--3.88)   0.538     2   0.41 (0.06--2.91)   0.369
  **FD-FH-NPC in stage I and II patients**                                                                                                                         
  Without                                                467      43    1.00                            31   1.00                         22   1.00                 
  With                                                    92      3     0.31 (0.07--1.34)   0.117        4   0.39 (0.05--2.99)   0.364     2   0.31 (0.04--2.35)   0.257
  **FD-FH-NPC in stage III and IV patients**                                                                                                                       
  Without                                                1099    295    1.00                            117  1.00                         191  1.00                 
  With                                                   115      17    0.57 (0.34--0.95)   0.033        7   0.54 (0.24--1.23)   0.143    11   0.49 (0.25--0.96)   0.036

Abbreviations: aHR=adjusted hazard ratio; CI=confidence interval; DMFS=distant metastasis-free survival; FD-FH-NPC=first-degree family history of nasopharyngeal carcinoma; LRFS=locoregional relapse-free survival; NPC=nasopharyngeal carcinoma; OS=overall survival.

Multivariate HRs and 95% CIs are adjusted for age group (categorical), gender, education degree (categorical), smoking status (never/current/former smoker), drinking status (never/current/former drinker), pathology (I/II/III), T stage (T1/T2/T3/T4), N stage (N0/N1/N2/N3), titre of VCA-IgA (**⩽**1 : 160 *vs* \>1 : 160), chemotherapy regimens and radiation technique.

###### Subgroup analysis of OS by patients\' characteristics in terms of with or without an FD-FH-NPC

                                              **No. of events/No. at risk**                               
  ------------------------- ------ --------- ------------------------------- -------- ------------------- -------
  Overall                   82.2                        338/1566              20/207  0.60 (0.37--0.98)   0.040
  **Age (years)**                  \<0.001                                                                 
  ⩽53                       86.3                        197/1159              12/158  0.67 (0.37--1.21)   0.187
  \>53                      70.1                         141/407               8/49   0.50 (0.20--1.23)   0.131
  **Gender**                       0.005                                                                   
  Male                      80.5                        276/1188              12/148  0.55 (0.30--0.98)   0.043
  Female                    87.2                         62/378                8/59   0.83 (0.33--2.10)   0.690
  **Education**                    \<0.001                                                                 
  Illiterate and primary    77.3                         163/600               9/67   0.48 (0.21--1.09)   0.079
  Secondary and higher      85.1                         175/966              11/140  0.72 (0.39--1.35)   0.306
  **Smoking status**               \<0.001                                                                 
  Yes                       76.2                         219/768              15/98   0.74 (0.41--1.34)   0.324
  No                        87.9                         119/798              5/109   0.41 (0.17--1.02)   0.056
  **Drinking status**              0.056                                                                   
  Yes                       78.5                         61/232                3/28   0.53 (0.13--2.26)   0.393
  No                        82.8                        277/1334              17/179  0.65 (0.39--1.11)   0.112
  **VCA-IgA**                      0.011                                                                   
  ⩽1 : 160                  84.5                         148/770              8/107   0.45 (0.18--1.10)   0.081
  \>1 : 160                 79.9                         190/796              12/100  0.73 (0.40--1.32)   0.294
  **Clinical stage**               \<0.001                                                                 
  I+II                      92.9                         43/467                3/92   0.31 (0.07--1.34)   0.117
  III+IV                    77.1                        295/1099              17/115  0.57 (0.34--0.95)   0.033
  **Chemotherapy**                 \<0.001                                                                 
  Yes                       80.1                        280/1209              16/136  0.57 (0.34--0.95)   0.030
  No                        88.6                         58/357                4/71   0.51 (0.18--1.45)   0.203
  **Radiation technique**          0.003                                                                   
  IMRT/3DCRT                86.9                         63/406                5/54   0.79 (0.28--2.23)   0.656
  Conventional              80.5                        275/1160              15/153  0.55 (0.31--0.96)   0.037

Abbreviations: aHR=adjusted hazard ratio; CI=confidence interval; FD-FH-NPC=first-degree family history of nasopharyngeal carcinoma; IMRT=intensity-modulated radiotherapy; OS=overall survival; VCA-IgA=immunoglobulin A against Epstein--Barr virus viral capsid antigen; 3DCRT=three-dimensional conformal radiotherapy.

Multivariate HRs and 95% CIs are adjusted for age group (categorical), gender, education degree (categorical), smoking status (never/current/former smoker), drinking status (never/current/former drinker), pathology (I/II/III), T stage (T1/T2/T3/T4), N stage (N0/N1/N2/N3), titre of VCA-IgA (**⩽**1 : 160 *vs* \>1 : 160), chemotherapy regimens and radiation technique.
